Allele burden of the JAK2 mutation also has an influence on disease phenotypes seen in polycythemia vera versus essential thrombocythemia, another related MPN in which about 50% of patients would harbor the JAK2 mutation. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.